-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Vascular liraglutide can increase the risk of diabetic retinopathy (including vitreous hemorrhage, diabetes-related blindness, and the need for photocoagulation or intra-bulbar injection of drugs, etc.
Purpose: Previous studies have shown that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may initially increase and aggravate the risk of diabetic retinopathy
Methods: Using the British Clinical Practice Research Data Link (CPRD), a cohort study was conducted on 77,115 patients with type 2 diabetes from January 2007 to September 2015
Results: During the 1-year follow-up of 245,825 people, 10763 patients were newly diagnosed with diabetic retinopathy
Table 1 Original and adjusted HRs associated with the use of GLP-1 RAs and the use of two or more oral hypoglycemic agents and the risk of diabetic retinopathy
a .
Table 2 Compared with insulin, the original and adjusted HRs between the use of GLP-1 RAs and the risk of diabetic retinopathy
a Every thousand people per year
The risk of diabetic retinopathy is related to different medications
Original source:
Douros A, Filion KB, Yin H, Yu OH, Etminan M, Udell JA, Azoulay L, Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy .
Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy
in this message
